Why is Bliss GVS Pharma falling/rising?

As of 19-Aug, Bliss GVS Pharma Ltd is currently priced at 173.15, reflecting a decrease of 1.25, or 0.72%. The stock has underperformed its sector today by 0.59%, despite trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has declined by 0.86%, although it has shown a positive return of 7.28% over the last month and an impressive 48.44% over the past year. Despite this strong yearly performance, the company has experienced a decline in profits by 3.6%, which may contribute to the current price movement. Additionally, there has been a decrease in investor participation, with delivery volume falling by 4.37% against the 5-day average. In the broader market context, the Sensex has increased by 1.76% over the past week, indicating that Bliss GVS Pharma's recent performance is lagging behind the overall market trend. While the stock has outperformed the BSE500 over the last three years, one year, and three months, its short-term performance does not align with the positive market sentiment. The company's low debt-to-equity ratio and fair valuation suggest stability, but the premium at which the stock is trading compared to its peers may be a concern for investors, especially in light of the recent profit decline. Overall, the combination of underperformance relative to the sector and reduced investor engagement appears to be influencing the stock's current downward movement.